Navigation Links
European Patent Office Upholds Molecular Devices Planar Patch Clamp Patent
Date:5/18/2010

SUNNYVALE, Calif., May 18 /PRNewswire/ -- Molecular Devices today announced that European Patent Office (EPO) has upheld Molecular Devices foundational planar patch-clamp patent (EP No 1 040 349 B1).  The board will issue a written decision to this effect in the near future. The ruling will be the final determination of the EPO and cannot be appealed.  

(Logo: http://www.newscom.com/cgi-bin/prnh/20100406/SF82092LOGO)

"Molecular Devices is extremely pleased that the European Patent Office will uphold our planar patch-clamp patent," said Mark Verheyden, President of Molecular Devices, Inc. "This planar patch clamp patent is one of several that are of strategic importance to our automated electrophysiology business. The innovation that went into these patents enables the development of next generation automated electrophysiology platforms, such as the IonWorks Barracuda™ High-Speed Automated Patch Clamp System."

The ruling recognizes Molecular Devices novel application of using an electric field to position and seal cells for electrophysiological measurement on a planar substrate. This capability has revolutionized the way pharmaceutical and biotechnology companies screen new chemical entities against ion channel targets implicated in diseases such as, hypertension, cardiac arrhythmias, cystic fibrosis, immune disorders, and pathological pain.

The European Patent was originally filed with the EPO on 28 July 1998 and granted on 05 September 2001. Opposition of the patent was filed by a single company on the grounds that particular prior art deprived the patents of novelty or inventiveness. On 14 April 2010, the EPO found the patent to be novel and inventive with an amended set of method claims.    

About Molecular Devices: At Molecular Devices we have one focus—our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire creative, best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dedicated follow-on support. Understanding your laboratory workflow is our top priority, and we direct product development toward solving your unique issues. Our instruments offer a full spectrum of detection technologies and meet all throughput needs—from dedicated, single-readout devices to multi-readout systems. Our goal is to deliver highly relevant analytical products to detect biology, decode data, and drive discovery. With headquarters in Silicon Valley and offices around the globe, we support and enrich efforts of the international BioResearch, BioPharma, and BioTesting communities. Visit us today at www.MolecularDevices.com.  

Molecular Devices®, the Molecular Devices logo, IonWorks®, IonWorks Barracuda™, and all other trademarks are the property of Molecular Devices, Inc.


'/>"/>
SOURCE Molecular Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... UNION CITY, Calif. , April 24, 2017 /PRNewswire/ ... providing durability, grip, protection, and comfort, announces the release ... the Powerform S8+. This most recent example of leading ... high density grip pattern for 200% more tactile grip ... in user protection and durability. With TracTek and a ...
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the ... devices, has been awarded a very significant patent for ... EMRs to continual care via digital health.  This landmark ... intellectual property and further secures Vivify,s position as the ... in 2009, was the first company to apply consumer ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... , ... TransDark is a set of dynamic transitions that feature inverted, prismatic, ... to set a single keyframe in Final Cut Pro X. Pick and ... features dynamic transitions that momentarily splits the RGB layers of pictures and videos before ...
(Date:4/29/2017)... ... , ... More than half of Americans suffering from noise-induced hearing loss do ... that causes hearing loss? May 1 marks the beginning of Better Hearing & Speech ... well as schedule a hearing evaluation for anyone with concerns about his/her hearing. , ...
(Date:4/28/2017)... ... 2017 , ... The National Campaign to Prevent Teen ... to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, introduced ... to ensure that all members of the Armed Forces receive high quality education ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more than ... (NSF), going just 19 hours without sleep can compromise motor reaction time, which can increase ... and Amica Insurance is sharing the following tips from the NSF to help you sleep ...
Breaking Medicine News(10 mins):